1-10 of 10
Jeremy S. Abramson
Close
Sort by
Journal Articles

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Clinical Trials & Observations
Inhye E. Ahn, Danielle M. Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A. Walker, Robert Black, Josie Montegaard, Alvaro Alencar, Leyla Shune, Mohammad Omaira, Caron A. Jacobson, Philippe Armand, Samuel Y. Ng, Jennifer Crombie, David C. Fisher, Ann S. LaCasce, Jon Arnason, Ephraim P. Hochberg, Ronald W. Takvorian, Jeremy S. Abramson, Jennifer R. Brown, Matthew S. Davids
Journal: Blood Advances
Blood Adv (2024) 8 (4): 832–841.
https://doi.org/10.1182/bloodadvances.2023011574
Published: 2024
Includes: Supplemental data
Journal Articles

Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma

Jee H. Choe, Tianzhou Yu, Jeremy S. Abramson, Mohamed Abou-el-Enein
Journal: Blood Advances
Blood Adv (2024) 8 (2): 484–496.
https://doi.org/10.1182/bloodadvances.2023011793
Published: 2024
Includes: Supplemental data
Journal Articles

Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma

Clinical Trials & Observations
Reem Karmali, Jeremy S. Abramson, Deborah M. Stephens, Jeffrey Barnes, Jane N. Winter, Shuo Ma, Juehua Gao, Jason Kaplan, Adam M. Petrich, Ephraim Hochberg, Tak Takvorian, Xinlei Mi, Valerie Nelson, Leo I. Gordon, Barbara Pro
Journal: Blood Advances
Blood Adv (2023) 7 (23): 7361–7368.
https://doi.org/10.1182/bloodadvances.2023011271
Published: 2023
Includes: Supplemental data
Journal Articles

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

Clinical Trials & Observations
Rahul Lakhotia, Kieron Dunleavy, Jeremy S. Abramson, Brian K. Link, Bayard L. Powell, Christopher Melani, Andrea N. Lucas, Seth M. Steinberg, Jonathan W. Friedberg, Brad S. Kahl, Richard F. Little, Nancy L. Bartlett, Ariela Noy, Wyndham H. Wilson, Mark Roschewski
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5320–5324.
https://doi.org/10.1182/bloodadvances.2023010223
Published: 2023
Journal Articles

Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma

Clinical Trials & Observations
Jeremy S. Abramson, Elizabeth Bengston, Robert Redd, Jeffrey A. Barnes, Tak Takvorian, Lubomir Sokol, Frederick Lansigan, Philippe Armand, Bijal Shah, Eric Jacobsen, Rosalba Martignetti, Elyce Turba, Sara Metzler, Victoria Patterson, Ann S. LaCasce, Celeste M. Bello
Journal: Blood Advances
Blood Adv (2023) 7 (7): 1130–1136.
https://doi.org/10.1182/bloodadvances.2022008420
Published: 2023
Journal Articles

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL

Clinical Trials & Observations
Jeremy S. Abramson, Patrick B. Johnston, Manali Kamdar, Sami Ibrahimi, Koji Izutsu, Jon Arnason, Bertram Glass, Pim Mutsaers, Matthew Lunning, Julia Braverman, Fei Fei Liu, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Shien Guo, Ling Shi, Scott R. Solomon
Journal: Blood Advances
Blood Adv (2022) 6 (23): 5969–5979.
https://doi.org/10.1182/bloodadvances.2022008106
Published: 2022
Includes: Supplemental data
Journal Articles

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study

Clinical Trials & Observations
J. Erika Haydu, Jenny S. Maron, Robert A. Redd, Kathleen M. E. Gallagher, Stephanie Fischinger, Jeffrey A. Barnes, Ephraim P. Hochberg, P. Connor Johnson, R. W. Takvorian, Katelin Katsis, Daneal Portman, Jade Ruiters, Sidney Sechio, Mary Devlin, Connor Regan, Kimberly G. Blumenthal, Aleena Banerji, Allen D. Judd, Krista J. Scorsune, Brianne M. McGree, Maryanne M. Sherburne, Julia M. Lynch, James I. Weitzman, Matthew Lei, Camille N. Kotton, Anand S. Dighe, Marcela V. Maus, Galit Alter, Jeremy S. Abramson, Jacob D. Soumerai
Journal: Blood Advances
Blood Adv (2022) 6 (6): 1671–1683.
https://doi.org/10.1182/bloodadvances.2021006627
Published: 2022
Includes: Supplemental data
Journal Articles

Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial

Jeremy S. Abramson, Tanya Siddiqi, Jacob Garcia, Christine Dehner, Yeonhee Kim, Andy Nguyen, Sophie Snyder, November McGarvey, Matthew Gitlin, Corey Pelletier, Monika P. Jun
Journal: Blood Advances
Blood Adv (2021) 5 (6): 1695–1705.
https://doi.org/10.1182/bloodadvances.2020003531
Published: 2021
Journal Articles

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia

Clinical Trials & Observations
Benjamin L. Lampson, Haesook T. Kim, Matthew S. Davids, Jeremy S. Abramson, Arnold S. Freedman, Caron A. Jacobson, Philippe A. Armand, Robin M. Joyce, Jon E. Arnason, Laura Z. Rassenti, Thomas J. Kipps, Joshua Fein, Stacey M. Fernandes, John R. Hanna, David C. Fisher, Jennifer R. Brown
Journal: Blood Advances
Blood Adv (2019) 3 (7): 1167–1174.
https://doi.org/10.1182/bloodadvances.2018030221
Published: 2019
Includes: Supplemental data
Journal Articles

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL

Clinical Trials & Observations
Monika Pilichowska, Stefania Pittaluga, Judith A. Ferry, Jessica Hemminger, Hong Chang, Jennifer A. Kanakry, Laurie H. Sehn, Tatyana Feldman, Jeremy S. Abramson, Athena Kritharis, Francisco J. Hernandez-Ilizaliturri, Izidore S. Lossos, Oliver W. Press, Timothy S. Fenske, Jonathan W. Friedberg, Julie M. Vose, Kristie A. Blum, Deepa Jagadeesh, Bruce Woda, Gaurav K. Gupta, Randy D. Gascoyne, Elaine S. Jaffe, Andrew M. Evens
Journal: Blood Advances
Blood Adv (2017) 1 (26): 2600–2609.
https://doi.org/10.1182/bloodadvances.2017009472
Published: 2017
Includes: Supplemental data